Last reviewed · How we verify
dinitrate isosorbide
Dinitrate isosorbide, marketed by Brugmann University Hospital, holds a position in the cardiovascular drug market with its key composition patent expiring in 2028. The drug's key strength lies in its established market presence and ongoing revenue generation, though specific figures are not disclosed. The primary risk is the potential increase in competition following the 2028 patent expiry, which could impact market share and revenue.
At a glance
| Generic name | dinitrate isosorbide |
|---|---|
| Sponsor | Brugmann University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Baroreflex Activation Therapy for Heart Failure (NA)
- Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy (PHASE1, PHASE2)
- DANHEART (H-HeFT and Met-HeFT) (PHASE4)
- Reduction of Cesareans by Nitric Oxide (NO) Donors in Post Term Pregnancies (PHASE3)
- Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT) (PHASE3)
- Treatment of Orthostatic Intolerance (PHASE1, PHASE2)
- Effect of Oral Isosorbide Mononitrate Plus Amlodipine Antispasm Therapy on Outcomes of Radial Artery Grafts After CABG (PHASE4)
- Cervical Ripening With Misoprostol vs Isosorbide Mononitrate ; A Parallel -Arm Randomized Controlled Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dinitrate isosorbide CI brief — competitive landscape report
- dinitrate isosorbide updates RSS · CI watch RSS
- Brugmann University Hospital portfolio CI